IMDX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 5.68%, SMA50 13.49%, SMA200 65.55%). The stock’s 14-day RSI is 57.57 (neutral), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -16.1% below its high and over 267.1% above its low. Average 10-day trading volume of 30.54 thousand shares is below the 3-month average of 51.58 thousand, indicating normal recent market interest.

Insight Molecular Diagnostics Inc. has 28.62 million shares outstanding. The public float is 7.78 million shares, elevated short interest at 2.05% of float. This equals 277.27 thousand shares. The short ratio is 5.46 days. Institutional investors hold 73.02% of the float. Insiders own 22.45%.

Insight Molecular Diagnostics Inc. generated EPS of -$2.83 over the past year. Five-year average earnings growth is 11.82%. Wall Street analysts project EPS growth of 49.38% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $4.25. The high target offers 26.05% upside. The low target suggests -40.48% downside. The mean target is $6.62. This offers -7.28% upside. Insight Molecular Diagnostics Inc. earnings surprise history is a mixed track record. The quarter that ended November 11, 2025, missed forecasts by -16.65%. The prior quarter beat by 47.83%. Over the last six quarters, Apple has recorded several small beats. These include 122.73% in November 12, 2024.

Our AI price prediction model suggests that Insight Molecular Diagnostics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.46%, with price expected at $6.75 by February 20, 2026, within a range of $6.34 to $7.17 3-Month Outlook: Projected rise of 122.97%, reaching $15.92 by May 07, 2026, with a range of $15.84 to $16.00. 1-Year Outlook: Projected gain of 419.05%, with price at $37.06 by February 05, 2027, within a range of $37.00 to $37.12.

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) closed at $7.14 USD, losing -$0.18 (-2.46%) from the previous close of $7.32. The stock is currently mid-range between its 52-week high and low $1.97 and $8.51. With a market capitalization of about $204.66 million, Insight Molecular Diagnostics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.35). Key stats such as the average daily volume over the past year has been around 51.17 thousand shares, in line with its 52-week average. Headquartered in Nashville, TN, Insight Molecular Diagnostics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joshua Riggs, the company employs approximately 46 people and listed since December 30, 2015. OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) shares are down -18.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Insight Molecular Diagnostics Inc. trading at a premium to the broader market with a P/E of -3.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.62, suggesting -7.28% downside. Our AI forecast model points to short-term weakness (-5.46% over two weeks), a medium-term rise (122.97% over three months), and a longer-term gain (419.05% over one year), with expected trading ranges indicating moderate volatility.

Insight Molecular Diagnostics Inc. trades at a P/E ratio of -3.82, slightly below the S&P 500 average, with a price-to-sales ratio of 47.21 and a price-to-book ratio of -25.25 indicating negative book value, which may reflect financial stress. The P/FCF stands at -8.69, also above market averages.